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Summary
Background.  —  Current  guidelines  for  the  prevention  of  cardiovascular  disease  emphasize  the
importance  of  assessing  global  cardiovascular  risk,  but  there  is  evidence  that  risk  is  often
assessed  inaccurately.
Aims.  —  To  compare  general  practitioner-reported  global  cardiovascular  risk  in  French  primary
care patients  with  estimates  based  on  established  risk-scoring  systems,  and  to  identify  factors
accounting for  any  mismatch  between  the  analyses.
Methods.  —  Data  on  patients  aged  greater  or  equal  to  50  years  seen  during  two  3-day  periods
were provided  by  619  general  practitioners.  Physicians  rated  each  patient’s  cardiovascular  risk
as low,  moderate  or  high,  according  to  their  perception;  in  addition,  risk  was  assessed  using
the Framingham  and  Systematic  coronary  risk  evaluation  (SCORE)  risk-scoring  systems.
Results.  —  A  total  of  13,446  patients  aged  greater  or  equal  to  50  years  were  included.  Of  11,241
patients with  no  previous  history  of  cardiovascular  disease,  47%  were  considered  by  their  physi-
cians to  be  at  low  risk  of  cardiovascular  disease  and  14%  to  be  at  high  risk.  In  that  population,
72% of  patients  rated  as  high  risk  according  to  the  Framingham  system  and  77%  rated  as  high  risk
according  to  SCORE  system  were  incorrectly  assessed  by  their  physicians;  similar  results  were
observed  in  patient  cohorts  based  on  whether  or  not  patients  had  received  treatment  for  dyslip-
idaemia.  Weighted  kappa  analysis  showed  poor  agreement  between  physician  risk  assessment
and both  the  Framingham  and  SCORE  risk-scoring  systems.
Abbreviations: GP, General practitioner; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; SCORE, Systematic coronary risk
evaluation; SD, Standard deviation; WK, Weighted kappa.
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Conclusion.  —  This  study  underlines  the  mismatch  between  GP-estimated  cardiovascular  risk
and the  risk  assessed  using  scoring  systems,  especially  for  high-risk  patients.
© 2011  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Rationnel.  — Les  recommandations  actuelles  concernant  la  prévention  des  maladies  cardiovas-
culaires  mettent  en  avant  l’importance  d’évaluer  le  risque  cardiovasculaire  global.  Ce  risque
est cependant  souvent  estimé  de  manière  insufﬁsante.
Objectifs.  —  Cette  étude  a  été  menée  dans  le  but  de  comparer  le  risque  évalué  par  les  médecins
généralistes  chez  les  patients  de  plus  de  50  ans,  au  risque  recalculé  par  les  échelles  de  risque,  et
de déterminer  quels  facteurs  étaient  déterminants  pour  la  discordance  entre  les  deux  analyses.
Méthodes.  —  Six  cent  dix-neuf  médecins  généralistes  ont  inclus  et  récupéré  les  informations
concernant  tous  les  patients  de  50  ans  et  plus  consultant  pendant  deux  périodes  de  trois
jours consécutifs.  Ils  devaient  estimer  le  risque  cardiovasculaire  de  chaque  patient  entre  bas,
modéré, sévère  ;  ce  risque  était  par  la  suite  recalculé  selon  les  échelles  de  Framingham  et  de
Systematic  Coronary  Risk  Evaluation  (SCORE).
Résultats.  —  Treize  mille  quatre  cent  quarante-six  patients  de  50  ans  ou  plus  ont  été  inclus  dans
l’étude. Parmi  les  11,241  patients  sans  antécédent  personnel  de  maladie  cardiovasculaire,  47  %
ont été  considérés  par  le  médecin  comme  étant  à  bas  risque  cardiovasculaire  et  14  %  à  haut
risque. Dans  cette  population,  le  risque  cardiovasculaire  avait  été  sous-évalué  par  les  médecins
chez 72  %  des  patients  évalués  à  haut  risque  selon  l’échelle  de  Framingham  et  77  %  de  ceux
évalués à  haut  risque  selon  SCORE  et  des  résultats  similaires  étaient  obtenus  selon  que  les
patient recevaient  ou  non  un  traitement  hypolipémiant.  Le  test  de  Kappa  pondéré  a  montré  qu’il
existait une  faible  concordance  entre  l’évaluation  du  risque  cardiovasculaire  par  les  médecins
généralistes  et  les  scores  de  Framingham  et  de  SCORE.
Conclusion.  —  Cette  étude  met  en  avant  la  discordance  entre  le  risque  estimé  par  les  médecins
généralistes  et  le  risque  évalué  par  les  échelles  de  risque,  particulièrement  chez  les  patients  à
haut risque  cardiovasculaire.
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ackground
urrent  guidelines  for  the  prevention  of  cardiovascular  dis-
ase  emphasize  the  importance  of  evaluating  a  patient’s
verall  (global)  cardiovascular  risk  —  a  process  that  requires
onsideration  of  both  modiﬁable  risk  factors,  such  as  hyper-
ension  and  dyslipidaemia,  and  non-modiﬁable  risk  factors
uch  as  age  and  sex  [1—3]. This  recommendation  is  based
pon  extensive  epidemiological  evidence,  which  shows  that
any  patients  have  multiple  cardiovascular  risk  factors,  and
hat  these  risk  factors  have  additive  or  synergistic  effects  on
he  overall  level  of  risk  [4—6]. The  impact  of  such  clustering
f  risk  factors  is  highlighted  by  data  from  the  Framingham
tudy,  which  showed  that  the  risk  of  coronary  heart  disease
n  patients  with  three  or  more  risk  factors  was  approximately
.4  times  higher  in  men,  and  almost  six  times  higher  in
omen,  compared  with  that  in  patients  with  no  risk  factors
6].
A  number  of  validated  risk-scoring  systems  are  available
or  the  estimation  of  global  cardiovascular  risk,  including
he  Framingham  risk-scoring  system  [7]  and  the  Systematic
oronary  risk  evaluation  (SCORE)  system  developed  by  the
uropean  Society  of  Cardiology  [8].  However,  there  is  evi-
ence  that,  despite  widespread  acceptance  of  the  concept
f  global  cardiovascular  risk,  risk  assessment  is  not  per-
ormed  routinely  in  clinical  practice.  For  example,  in  a
urvey  of  754  general  practitioners  (GPs)  in  ﬁve  European
ountries  (France,  Germany,  Italy,  Sweden  and  the  UK),
T
ss  droits  réservés.
1% of  respondents  reported  using  the  current  guidelines
ut  only  18%  thought  that  the  guidelines  were  being  widely
mplemented  [9].  Furthermore,  there  is  evidence  that  risk
s  often  estimated  inaccurately  even  when  guidelines  are
ollowed.  For  example,  in  the  CONTROLRISK  study  in  Spain,
ardiovascular  risk  was  correctly  estimated  in  only  48%  of
atients  treated  in  primary  care  and  in  55%  of  those  treated
y  specialists  [10]. Similar  results  were  obtained  in  a  study
n  hypertensive  primary  care  patients  in  the  UK,  in  which
lobal  cardiovascular  risk  (assessed  using  Framingham-based
ables)  was  correctly  estimated  in  only  21%  of  patients  and
as  under-estimated  in  63%  [11].
To  our  knowledge,  no  studies  have  evaluated  cardiovas-
ular  risk  assessment  in  French  patients.  Hence,  the  present
tudy  was  undertaken  to  compare  assessments  of  cardiovas-
ular  risk  by  French  primary  care  physicians  with  the  actual
evel  of  risk,  as  calculated  using  the  Framingham  and  SCORE
ystems,  and  to  identify  potential  factors  associated  with
naccurate  risk  estimation.  This  paper  presents  results  from
atients  without  a  previous  history  of  cardiovascular  disease
i.e.  candidates  for  primary  prevention  of  cardiovascular
isease).
ethodshe  study  was  a  survey  of  619  French  GPs.  The  physician
ample  was  chosen  from  the  online  Kantar  Health  France
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BCardiovascular  risk  assessment  in  French  primary  care  patie
panel  of  4134  primary  care  physicians  and  was  representa-
tive  of  primary  care  physicians.  A  total  of  3885  GPs  were  sent
an  e-mail  invitation  to  participate  in  the  study.  Participating
physicians  were  asked  to  complete  an  online  questionnaire
for  all  patients  aged  50  years  and  older  who  were  seen  dur-
ing  one  of  two  3-day  periods  (16—18  December  2009  and
11—13  January  2010).  In  addition,  physicians  were  asked  to
estimate  the  patient’s  level  of  cardiovascular  risk  on  a  three-
point  scale  (low,  medium,  or  high).  Risk  scores  for  each
patient  were  also  assessed  according  to  the  Framingham  [7]
and  SCORE  [8]  (for  countries  with  low  cardiovascular  risk)
systems  using  published  algorithms  [7,8]. Risk  was  analysed
according  to  the  Framingham  system  (low,  ≤  10%;  interme-
diate,  10%  to  ≤  20%;  high,  >  20%)  and  the  SCORE  system  (low,
<  2%;  intermediate,  2—4%;  high  ≥  5%).
To  allow  analysis  according  to  the  total  number  of  consul-
tations,  each  doctor  received  a  weighting  [12]  based  on  the
geographical  region  in  which  they  practised,  and  the  num-
ber  of  consultations  was  weighted  according  to  the  relative
number  of  GP  consultations  in  France  and  the  age  and  sex
distribution  of  the  French  population.  All  data  relating  to
the  total  number  of  consultations  were  adjusted  based  on
this  weighting.
The  data  analysis  was  essentially  descriptive.  Due  to
potential  gain  in  cardiovascular  risk  control,  two  cohorts  of
patients  were  analysed:  those  who  were  receiving  treatment
for  dyslipidaemia  and  those  who  were  not.  Analysis  was  per-
formed  using  QUANTUM® software,  version  5.8.  Student’s  t
test  was  used  at  a  level  of  95—99%  (i.e.  1—5%  risk  of  error).
Bases  with  less  than  30  individuals  are  not  statistically  sig-
niﬁcant  for  this  test.
Results
The  mean  age  (standard  deviation  [SD])  of  the  participat-
ing  physicians  was  49.7  (7.8)  years  (50.0  [7.8]  years  after
adjustment  for  weighting);  83%  were  men.  Approximately
16%  were  practising  in  the  Paris  area  and  similar  propor-
tions  were  practising  in  all  other  regions  of  France.  Overall,
participating  GPs  believed  that  the  two  3-day  study  periods
were  typical  of  their  usual  practice  workload.
Study population
The  619  participating  physicians  provided  data  for  a  total
of  13,483  patients  (average  22  patients  per  GP),  of  whom
37  were  excluded  because  of  abnormal  ﬁndings.  Patients
excluded  from  the  analysis  were  those  for  whom  blood  pres-
sure,  total  cholesterol,  triglyceride,  high-density  lipoprotein
(HDL)  and  low-density  lipoprotein  (LDL)  values  were  incon-
sistent.  Of  the  remaining  13,446  patients,  6380  (47%)  were
aged  50—64  years  and  7066  (53%)  were  aged  65  years  or
older.  A  total  of  11,241  patients  (84%)  had  no  previous  history
of  cardiovascular  disease  and  were  included  in  the  analysis.
Of  these,  3359  (30%)  were  receiving  treatment  for  dyslipi-
daemia  with  statins  or  other  lipid-lowering  drugs.Table  1  summarizes  the  cardiovascular  risk  factors
present  in  the  overall  study  population,  the  primary  pre-
vention  population,  and  the  cohorts  that  were  treated  or
untreated  for  dyslipidaemia.  For  patients  that  had  had
t
t
1
aigure 1. Risk estimate and risk calculation with the Framingham
nd Systematic coronary risk evaluation (SCORE) systems for the pri-
ary prevention population (n = 11,241). GP: general practitioner.
 carotid  ultrasonography  (prescribed  by  a  GP  or  spe-
ialist),  results  are  presented  depending  on  the  reported
therosclerosis  severity  (none,  mild,  obstructive).  In  the
verall  study  population,  the  average  number  of  risk  fac-
ors  per  patient,  as  deﬁned  by  the  Agence  Francaise  de
écurité  Sanitaire  des  Produits  de  Santé,  was  1.7;  45%  of
atients  had  elevated  LDL-cholesterol,  29%  had  uncontrolled
ypertension  and  18%  had  diabetes  (Table  1).  In  the  primary
revention  population,  the  mean  number  of  risk  factors
er  patient  was  1.5  and  the  incidence  of  individual  risk
actors  was  similar  to  that  in  the  overall  study  population
Table  1).
ardiovascular risk estimation for primary
revention population
verall,  47%  of  patients  in  the  primary  prevention  pop-
lation  were  considered  by  their  GPs  to  be  at  low  risk
f  cardiovascular  disease  and  14%  were  considered  to
e  at  high  risk  (Fig.  1).  Comparison  with  the  levels  of
isk  obtained  with  the  Framingham  and  SCORE  systems
uggested  that  high  levels  of  risk  were  widely  under-
stimated  (Fig.  1).  Using  the  Framingham  risk  assessments
s  a  basis,  it  was  calculated  that  only  45%  of  high-
isk  patients  were  correctly  identiﬁed  by  their  GPs:  risk
as  over-estimated  in  29%  and  under-estimated  in  26%
Table  2).  Similarly,  using  the  SCORE  assessments  as  a
asis,  which  exclude  diabetes  as  a  cardiovascular  risk  fac-
or,  only  41%  of  high-risk  patients  were  correctly  identiﬁed
Table  2).
A further  analysis  assessed  levels  of  cardiovascular  risk
ccording  to  the  Framingham  and  SCORE  systems  (Table  3).
oth  analyses  excluded  2604  patients  with  poorly  con-
rolled  dyslipidaemia,  or  whose  lipid  status  was  unknown
o  their  GP.  In  addition,  the  Framingham  analysis  excluded
54  patients  with  type  1  diabetes  mellitus  [7];  thus,  this
nalysis  included  8483  patients.  The  latter  patients  were
384  É.  Bruckert  et  al.
Table  1  Cardiovascular  risk  factors  in  the  overall  study  population  and  in  primary  prevention  patients  with  no  history
of  cardiovascular  disease.
Overall  study
population
(n  =  13,446)
Primary  prevention  population
Total
(n  =  11,241)
Not  treated  for
dyslipidaemia
(n  =  7882)
Treated  for
dyslipidaemia
(n  =  3359)
Sex,  men/women  (%) 48/52 45/55 43/57 51a/49
Mean  age  (years) 66.7 65.9 65.2 67.8a
Total  cholesterol  >  2.4  g/L  (%)  17  17  18a 15
LDL-cholesterol  ≥  1.3  g/L  (%)  45  48  52a 41
HDL-cholesterol  ≥  0.6  g/L  (%)  36  38  40a 33
TG  >  2g/L  (%)  10  10  8  12a
Family  history  of
cardiovascular  disease  (%)
16 8  6  14a
Smoker  (%)  14  13  13  15a
Uncontrolled  high  blood
pressure  (%)
29 28  25  36a
Diabetes  (%) 18  15  9  29a
Mild  atherosclerosis  on  US
examination  (%)
18  13  7  27a
Obstructive  carotid  plaque  on
US  examination  (%)
4 2 1  5
Chronic  inﬂammatory  disease
(%)
14 13 13 14
HDL: high-density lipoprotein; LDL: low-density lipoprotein; TG: triglyceride; US: ultrasound examination.
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ncluded  in  the  SCORE  analysis,  which  therefore  included
637  patients.  This  analysis  showed  that  72%  of  patients
ated  as  high  risk  according  to  the  Framingham  system  and
7%  of  patients  rated  as  high  risk  according  to  the  SCORE
ystem  were  incorrectly  assessed  by  their  GPs  (Table  3).
his  mismatch  between  GP  assessment  of  cardiovascular
isk  and  the  real  calculated  level  of  risk  was  different
epending  on  whether  or  not  patients  were  treated  for  dys-
ipidemia.  For  the  total  population  in  primary  prevention,
eighted  kappa  (WK)  analysis  showed  a  lack  of  agreement
etween  physician  risk  assessment  and  both  the  Framing-
am  system  (WK,  0.21;  90%  conﬁdence  interval  0.20—0.23)
nd  the  SCORE  system  (WK,  0.19;  90%  conﬁdence  interval
.18—0.21).
A
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Table  2  Proportion  of  high-risk  patients  correctly  identiﬁed
assessments  performed  using  the  Framingham  or  Systemic  Coro
Framingham
Accurately
estimated
Over-
estimated
Primary  prevention
population  (%)  (n  =  11,241)
45  29  
Not  treated  for  dyslipidaemia
(%)  (n  =  7882)
49 22  
Treated  for  dyslipidaemia  (%)
(n  =  3359)
38  41  atients in primary prevention not receiving
reatment for dyslipidaemia
verall,  41%  of  patients  who  were  not  receiving  treatment
or  dyslipidaemia  were  considered  by  their  GPs  to  be  at
oderate  or  high  risk  of  cardiovascular  disease;  by  con-
rast,  46%  and  60%  were  estimated  to  be  at  moderate  or
igh  risk  using  the  Framingham  and  SCORE  systems,  respec-
ively  (Fig.  2).  The  proportions  of  patients  identiﬁed  by  the
ramingham  and  SCORE  systems  who  were  correctly  identi-
ed  by  their  GPs  were  49%  and  43%,  respectively  (Table  2).
nalysis  according  to  the  Framingham  and  SCORE  systems
howed  that  81%  and  86%  of  high-risk  patients,  respectively,
ere  inaccurately  rated  by  their  GPs  (Table  3).
 by  their  general  practitioner,  in  comparison  with  risk
nary  Risk  Evaluation  (SCORE)  systems.
SCORE
Under-
estimated
Accurately
estimated
Over-
estimated
Under-
estimated
26  41  20  39
29  43  15  42
21  38  28  34
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Figure 2. Risk estimate and risk calculation with the Framing-
ham and Systematic coronary risk evaluation (SCORE) systems for
the primary prevention population not treated for dyslipidaemia
(n = 7882). GP: general practitioner.
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0In  this  population  of  patients  not  receiving  treatment  for
yslipidaemia,  the  Framingham  system  showed  that  54%  of
en  aged  50  years  or  older  and  who  were  smokers,  and  69%
f  men  aged  50  years  or  more  with  hypertension  and  low  HDL
ere  at  high  cardiovascular  risk.  Similarly,  with  the  SCORE
ystem,  51%  of  men  aged  50  years  or  more  with  hypertension
nd  53%  of  women  aged  60  years  or  more  with  hypertension
ere  at  high  cardiovascular  risk.
For  patients  in  primary  prevention  not  receiving  treat-
ent  for  dyslipidaemia,  WK  analysis  showed  a  lack  of
greement  between  physician  risk  assessment  and  both
he  Framingham  system  (WK,  0.21;  90%  conﬁdence  interval
.19—0.23)  and  the  SCORE  system  (WK,  0.19;  90%  conﬁdence
nterval  0.17—0.21).
atients receiving treatment for dyslipidaemia
 total  of  81%  of  patients  who  were  receiving  treatment
or  dyslipidaemia  were  considered  by  their  GPs  to  be  at
oderate  or  high  cardiovascular  risk;  the  corresponding  pro-
ortions  based  on  the  Framingham  and  SCORE  criteria  were
8%  and  73%,  respectively.  Only  38%  of  patients  were  cor-
ectly  identiﬁed  by  their  GPs  according  to  the  Framingham
r  SCORE  systems  (Table  2).  Similarly,  analysis  according
o  the  Framingham  or  SCORE  criteria  showed  that  high-risk
atients  were  inaccurately  assessed  in  60%  and  65%  of  cases,
espectively  (Table  3).
For  patients  in  primary  prevention  receiving  treatment
or  dyslipidaemia,  WK  analysis  showed  a  lack  of  agreement
etween  physician  risk  assessment  and  both  the  Framing-
am  system  (WK,  0.15;  90%  conﬁdence  interval  0.13—0.17)
nd  the  SCORE  system  (WK,  0.12;  90%  conﬁdence  interval
.09—0.14).
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isk-scoring  systems  classify  patients  into  several  categories
ccording  to  their  risk  factors,  enabling  physicians  to  make
ppropriate  treatment  decisions  and  reduce  the  risk  of  car-
iovascular  events.  However,  evidence  shows  that  these
ystems  are  not  systematically  used  by  GPs,  leading  to
nappropriate  identiﬁcation  of  cardiovascular  risk  level  and
herefore  subsequent  treatment.  Application  of  the  Fram-
ngham  and  SCORE  risk-evaluation  systems  to  the  patients
n  this  study  showed  that  at  least  half  of  the  patients  were
t  moderate  or  high  cardiovascular  risk.  This  is  consistent
ith  the  results  of  studies  from  other  countries,  which  show
hat  high-risk  patients  are  a  common  ﬁnding  in  routine
linical  practice.  For  example,  in  a  study  of  4059  hyper-
ensive  patients  in  Italy,  56.5%  were  considered  to  be  at
igh  or  very  high  risk  according  to  the  World  Health  Orga-
ization/International  Society  of  Hypertension  guidelines,
lthough  only  35.8%  of  these  were  considered  by  their  physi-
ians  to  be  at  high  risk  [13].
The  characteristics  of  patients  considered  to  be  at  high
ardiovascular  risk  were  examined  in  the  cohort  of  patients
ho  were  not  receiving  treatment  for  dyslipidaemia.  As
ight  be  expected,  high  cardiovascular  risk  tended  to  be
ssociated  with  age  over  50  years  in  men  and  over  60  years
n  women,  and  the  proportion  of  patients  considered  to  be  at
igh  risk  tended  to  increase  with  the  number  of  risk  factors
resent.
The  large  proportion  of  high-risk  patients  in  the  present
tudy  is  perhaps  not  surprising  given  that  most  patients  had
ore  than  one  cardiovascular  risk  factor.  However,  despite
he  high  prevalence  of  such  risk  factors,  cardiovascular  risk
as  accurately  assessed  in  only  a  minority  of  patients;  this
nding  is  also  consistent  with  previous  studies  in  other  Euro-
ean  countries  [10,11,13]. The  level  of  cardiovascular  risk,
s  assessed  using  the  Framingham  system,  was  correctly
ssessed  in  only  28—53%  of  patients.  However,  a  recognized
imitation  of  the  Framingham  system  is  that  it  was  validated
sing  data  from  a  large  US  population,  and  as  such  cannot
eadily  be  extrapolated  to  European  countries,  particularly
ountries  where  the  risk  of  cardiovascular  disease  is  low
such  as  France)  [14,15].  Comparison  of  the  GP  estimates  in
he  present  study  with  those  derived  using  the  SCORE  system
ay  thus  be  more  informative,  because  the  SCORE  system
as  developed  for  use  in  European  populations  and  includes
peciﬁc  charts  for  low-risk  and  high-risk  countries  [8,15].
owever,  due  to  the  original  study  population,  the  SCORE
ystem  has  never  been  validated  for  patients  older  than  65
ears,  even  though  the  formula  allows  the  calculation.  In  our
tudy,  patients  at  high  risk,  as  assessed  by  the  SCORE  system,
ere  inaccurately  assessed  by  their  GPs  in  77%  of  cases,  and
his  increased  to  86%  in  the  cohort  who  were  not  receiv-
ng  treatment  for  dyslipidaemia;  indeed,  even  in  patients
eceiving  lipid-lowering  therapy  (in  whom  the  index  of  suspi-
ion  for  cardiovascular  risk  might  be  expected  to  be  raised),
5%  of  those  at  highest  risk  were  incorrectly  assessed  by
heir  GPs.  This  discrepancy  between  real  and  GP-reported
ardiovascular  risk  level  suggests  that  GPs  undertake  an
mpirical  examination  without  considering  all  risk  factors  in
heir  diagnosis.  One  of  the  reasons  for  the  under-utilization
f  risk  assessment  systems  is  probably  the  fact  that  high
ardiovascular  perception  is  frequently  associated  withÉ.  Bruckert  et  al.
econdary  prevention  only  and  it  is  thought  that  patients
n  primary  prevention  could  not  have  such  a  high  cardiovas-
ular  risk.  This  has  to  be  added  to  the  classical  reasons  for
he  under-use  of  such  scoring  systems  (lack  of  time  and/or
onﬁdence).
Some  limits  should  be  noticed  in  our  study.  The  Framing-
am  and  SCORE  systems  are  not  assessing  exactly  the  same
isk.  Indeed,  Framingham  evaluated  the  10-year  risk  of  coro-
ary  heart  disease  risk  and  SCORE  evaluated  the  10-year  risk
f  fatal  cardiovascular  disease.  Furthermore,  the  items  used
o  assess  the  risk  are  not  the  same  in  the  two  formulae  (i.e.
CORE  does  not  include  diabetes  in  its  evaluation).  These
ifferences  limit  the  comparisons  between  the  two  scoring
ystems.  It  should  also  be  noticed  that  these  formulae  allow
isk  assessment  for  untreated  patients  and  that  they  could
heoretically  not  be  used  for  patients  receiving  treatment
or  dyslipidemia.
onclusion
his  study  has  shown  that  a  high  proportion  of  patients  pre-
enting  to  primary  care  physicians  in  France  are  at  high  risk
f  cardiovascular  disease.  However,  there  is  a  marked  mis-
atch  between  GP  assessment  of  cardiovascular  risk  and  the
ctual  level  of  risk  as  calculated  by  risk-scoring  systems  such
s  Framingham  or  SCORE.  Thus,  GPs  should  be  encouraged
o  use  risk-scoring  systems  in  order  to  better  predict  the  risk
f  cardiovascular  events  and  adapt  treatment  accordingly.
isclosure of interest
enevieve  Bonnelye  is  an  employee  of  Kantar  Health.  Lucas
ndré,  Florence  Thomas-Delecourt  and  Pierre-Henri  Delaage
re  employees  of  AstraZeneca  France.
cknowledgments
ditorial  support  during  the  preparation  of  the  manuscript
as  provided  by  Ann  McIlhinney,  DPhil,  Anagram  Communi-
ations  Ltd.  (Oxford,  UK),  supported  by  AstraZeneca  France.
he  study  was  sponsored  by  AstraZeneca  France.
eferences
[1] 2003 European Society of Hypertension-European Society of
Cardiology guidelines for the management of arterial hyper-
tension. J Hypertens 2003;21:1011—53.
[2] De Backer G, Ambrosioni E, Borch-Johnsen K, et al. Euro-
pean guidelines on cardiovascular disease prevention in clinical
practice. Third Joint task force of European and other Societies
on cardiovascular disease prevention in clinical practice. Eur
Heart J 2003;24:1601—10.
[3] Whitworth JA. 2003 World Health Organization
(WHO)/International Society of Hypertension (ISH) state-
ment on management of hypertension. J Hypertens
2003;21:1983—92.
[4] Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk
factors, and 12-yr cardiovascular mortality for men screened
nts  
[
[
[
[
[Cardiovascular  risk  assessment  in  French  primary  care  patie
in the Multiple Risk Factor Intervention Trial. Diabetes Care
1993;16:434—44.
[5] Thomas F, Rudnichi A, Bacri AM, et al. Cardiovascular mortality
in hypertensive men according to presence of associated risk
factors. Hypertension 2001;37:1256—61.
[6] Wilson PW, Kannel WB, Silbershatz H, et al. Clustering of
metabolic factors and coronary heart disease. Arch Intern Med
1999;159:1104—9.
[7] Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coro-
nary heart disease using risk factor categories. Circulation
1998;97:1837—47.
[8] Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-
year risk of fatal cardiovascular disease in Europe: the SCORE
project. Eur Heart J 2003;24:987—1003.
[9] Hobbs FD, Erhardt L. Acceptance of guideline recommenda-
tions and perceived implementation of coronary heart disease
prevention among primary care physicians in ﬁve European
countries: the Reassessing European Attitudes about Cardiovas-
cular Treatment (REACT) survey. Fam Pract 2002;19:596—604.
[387
10] Barrios V, Escobar C, Calderon A, et al. Cardiovascular risk
proﬁle and risk stratiﬁcation of the hypertensive population
attended by general practitioners and specialists in Spain. The
CONTROLRISK study. J Hum Hypertens 2007;21:479—85.
11] Montgomery AA, Fahey T, MacKintosh C, et al. Estimation of
cardiovascular risk in hypertensive patients in primary care. Br
J Gen Pract 2000;50:127—8.
12] Deville JC, Särndal CE, Sautory O. Generalized raking proce-
dures in survey sampling. J Am Statist Assoc 1993;88:1013—20.
13] Mancia G, Volpe R, Boros S, et al. Cardiovascular risk proﬁle and
blood pressure control in Italian hypertensive patients under
specialist care. J Hypertens 2004;22:51—7.
14] Empana JP, Ducimetiere P, Arveiler D, et al. Are the Fram-
ingham and PROCAM coronary heart disease risk functions
applicable to different European populations? The PRIME Study.
Eur Heart J 2003;24:1903—11.
15] Zannad F, Jakobsen A, Heroys J, et al. Cardiovascular high-
risk patients—treat to protect, but whom? Medscape J Med
2008;10(Suppl.):S2.
